- VAL-083 Did Not Perform Better Than Current Standards of Care -
- Company Suspending Development of VAL-083, Shifting Focus to REM-001 Program and Other Strategic Opportunities -
https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-preliminary-topline-results-from-gbm-agile-study-301972323.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.